

Martha C Nason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2447428/publications.pdf>

Version: 2024-02-01

96
papers

17,239
citations

36303

51
h-index

39675

94
g-index

104
all docs

104
docs citations

104
times ranked

20738
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	28.9	64
2	mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. <i>Cell</i> , 2022, 185, 1556-1571.e18.	28.9	179
3	Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial. <i>EClinicalMedicine</i> , 2022, 48, 101477.	7.1	13
4	Placebo-Controlled Trials of Covid-19 Vaccines “ Why We Still Need Them. <i>New England Journal of Medicine</i> , 2021, 384, e2.	27.0	66
5	Clinical Endpoints for Evaluating Efficacy in COVID-19 Vaccine Trials. <i>Annals of Internal Medicine</i> , 2021, 174, 221-228.	3.9	86
6	COVID-19 vaccine trials: The use of active controls and non-inferiority studies. <i>Clinical Trials</i> , 2021, 18, 335-342.	1.6	22
7	PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors. <i>Clinical Infectious Diseases</i> , 2021, 73, 1849-1856.	5.8	24
8	Adjustment for Disease Severity in the Test-Negative Study Design. <i>American Journal of Epidemiology</i> , 2021, 190, 1882-1889.	3.4	6
9	Broadly neutralizing antibody-mediated protection of macaques against repeated intravenous exposures to simian-human immunodeficiency virus. <i>Aids</i> , 2021, 35, 1567-1574.	2.2	6
10	COVID-19 vaccine trials: The potential for “hybrid” analyses. <i>Clinical Trials</i> , 2021, 18, 391-397.	1.6	4
11	Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. <i>Nature</i> , 2021, 595, 289-294.	27.8	68
12	The mechanistic analysis of founder virus data in challenge models. <i>Statistics in Medicine</i> , 2021, 40, 4492-4504.	1.6	2
13	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	3.9	15
14	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	14.5	57
15	Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 1372-1377.	12.6	459
16	Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, 2348-2360.	27.0	458
17	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. <i>Science</i> , 2021, 373, eabj0299.	12.6	244
18	Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1111-1120.	10.7	38

#	ARTICLE	IF	CITATIONS
19	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	12.6	83
20	Longitudinal Antibody Responses in People Who Inject Drugs Infected With Similar Human Immunodeficiency Virus Strains. <i>Journal of Infectious Diseases</i> , 2020, 221, 756-765.	4.0	2
21	Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. <i>Clinical Infectious Diseases</i> , 2020, 71, 652-660.	5.8	44
22	Adaptive Viral Load Monitoring Frequency to Facilitate Differentiated Care: A Modeling Study From Rakai, Uganda. <i>Clinical Infectious Diseases</i> , 2020, 71, 1017-1021.	5.8	3
23	SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. <i>Nature</i> , 2020, 586, 567-571.	27.8	1,153
24	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. <i>New England Journal of Medicine</i> , 2020, 383, 1544-1555.	27.0	936
25	Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	30
26	Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks. <i>New England Journal of Medicine</i> , 2020, 382, 1366-1369.	27.0	63
27	Patterns of signs, symptoms, and laboratory values associated with Zika, dengue, and undefined acute illnesses in a dengue endemic region: Secondary analysis of a prospective cohort study in southern Mexico. <i>International Journal of Infectious Diseases</i> , 2020, 98, 241-249.	3.3	8
28	Cardiovascular Biomarker Profile on Antiretroviral Therapy Is Not Influenced by History of an IRIS Event in People With HIV and Suppressed Viremia. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa017.	0.9	0
29	A proof of concept for structure-based vaccine design targeting RSV in humans. <i>Science</i> , 2019, 365, 505-509.	12.6	207
30	Design of vaccine efficacy trials during public health emergencies. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	41
31	Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study. <i>Lancet</i> , The, 2019, 393, 889-898.	13.7	99
32	Taking stock of the present and looking ahead: envisioning challenges in the design of future HIV prevention efficacy trials. <i>Lancet HIV</i> , the, 2019, 6, e475-e482.	4.7	19
33	Hypomorphic caspase activation and recruitment domain 11 (CARD11) mutations associated with diverse immunologic phenotypes with or without atopic disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1482-1495.	2.9	116
34	Susceptibility to SIV Infection After Adenoviral Vaccination in a Low Dose Rhesus Macaque Challenge Model. <i>Pathogens and Immunity</i> , 2019, 4, 1.	3.1	3
35	A boundary-optimized rejection region test for the two-sample binomial problem. <i>Statistics in Medicine</i> , 2018, 37, 1047-1058.	1.6	5
36	Type I IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication. <i>PLoS Pathogens</i> , 2018, 14, e1007246.	4.7	33

#	ARTICLE	IF	CITATIONS
37	Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies. <i>Immunity</i> , 2018, 49, 301-311.e5.	14.3	110
38	Response to letter by Antonio Martn Andrs on "A boundary-optimized rejection region test for the two-sample binomial problem". <i>Statistics in Medicine</i> , 2018, 37, 2303-2306.	1.6	0
39	Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2711-2716.	7.1	201
40	Lymph Node Activation by PET/CT Following Vaccination With Licensed Vaccines for Human Papillomaviruses. <i>Clinical Nuclear Medicine</i> , 2017, 42, 329-334.	1.3	63
41	Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. <i>New England Journal of Medicine</i> , 2017, 377, 1438-1447.	27.0	199
42	Reduced Frequency of Cells Latently Infected With Replication-Competent Human Immunodeficiency Virus-1 in Virally Suppressed Individuals Living in Rakai, Uganda. <i>Clinical Infectious Diseases</i> , 2017, 65, 1308-1315.	5.8	20
43	Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012). <i>PLoS ONE</i> , 2016, 11, e0166393.	2.5	14
44	Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. <i>Nature Medicine</i> , 2016, 22, 614-623.	30.7	313
45	A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. <i>Nature</i> , 2016, 533, 105-109.	27.8	281
46	Rapid development of a DNA vaccine for Zika virus. <i>Science</i> , 2016, 354, 237-240.	12.6	348
47	Statistics and logistics: Design of Ebola vaccine trials in West Africa. <i>Clinical Trials</i> , 2016, 13, 87-91.	1.6	11
48	Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challenges. <i>Clinical Trials</i> , 2016, 13, 49-56.	1.6	63
49	Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs. <i>Journal of Virology</i> , 2016, 90, 1321-1332.	3.4	68
50	Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials. <i>PLoS ONE</i> , 2015, 10, e0136626.	2.5	23
51	HIV-1 Fitness Cost Associated with Escape from the VRC01 Class of CD4 Binding Site Neutralizing Antibodies. <i>Journal of Virology</i> , 2015, 89, 4201-4213.	3.4	121
52	Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. <i>Science Translational Medicine</i> , 2015, 7, 309ra162.	12.4	312
53	Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011). <i>PLoS ONE</i> , 2014, 9, e91366.	2.5	23
54	Homologous Boosting with Adenoviral Serotype 5 HIV Vaccine (rAd5) Vector Can Boost Antibody Responses despite Preexisting Vector-Specific Immunity in a Randomized Phase I Clinical Trial. <i>PLoS ONE</i> , 2014, 9, e106240.	2.5	5

#	ARTICLE	IF	CITATIONS
55	Comparison of adaptive and innate immune responses induced by licensed vaccines for human papillomavirus. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3446-3454.	3.3	50
56	Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor. <i>Science Translational Medicine</i> , 2014, 6, 243ra88.	12.4	222
57	Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV. <i>Nature</i> , 2014, 505, 502-508.	27.8	140
58	Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. <i>Journal of Experimental Medicine</i> , 2014, 211, 2061-2074.	8.5	297
59	Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody <i>In Vitro</i> Improves Protection against Lentiviral Infection <i>In Vivo</i> . <i>Journal of Virology</i> , 2014, 88, 12669-12682.	3.4	248
60	Type I interferon responses in rhesus macaques prevent SIV infection and slow disease progression. <i>Nature</i> , 2014, 511, 601-605.	27.8	422
61	Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. <i>Nature</i> , 2014, 514, 642-645.	27.8	308
62	Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine. <i>Science</i> , 2013, 341, 1359-1365.	12.6	686
63	Delineating Antibody Recognition in Polyclonal Sera from Patterns of HIV-1 Isolate Neutralization. <i>Science</i> , 2013, 340, 751-756.	12.6	213
64	Early immunologic and virologic predictors of clinical HIV-1 disease progression. <i>Aids</i> , 2013, 27, 697-706.	2.2	13
65	DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial. <i>PLoS ONE</i> , 2013, 8, e59340.	2.5	71
66	Virus Inhibition Activity of Effector Memory CD8 ⁺ T Cells Determines Simian Immunodeficiency Virus Load in Vaccinated Monkeys after Vaccine Breakthrough Infection. <i>Journal of Virology</i> , 2012, 86, 5877-5884.	3.4	37
67	HIV-1 Neutralization Coverage Is Improved by Combining Monoclonal Antibodies That Target Independent Epitopes. <i>Journal of Virology</i> , 2012, 86, 3393-3397.	3.4	71
68	Decreased Pre-existing Ad5 Capsid and Ad35 Neutralizing Antibodies Increase HIV-1 Infection Risk in the Step Trial Independent of Vaccination. <i>PLoS ONE</i> , 2012, 7, e33969.	2.5	22
69	A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial. <i>Journal of Infectious Diseases</i> , 2011, 203, 1396-1404.	4.0	138
70	Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. <i>Blood</i> , 2011, 117, 4805-4815.	1.4	193
71	An Augmented Probit Model for Missing Predictable Covariates in Quantal Bioassay with Small Sample Size. <i>Biometrics</i> , 2011, 67, 1127-1134.	1.4	1
72	A Note on Correction of Information Time in a Survival Trial Using an Alpha Spending Function. <i>Statistics in Biosciences</i> , 2011, 3, 250-259.	1.2	2

#	ARTICLE	IF	CITATIONS
73	SPICE: Exploration and analysis of post-cytometric complex multivariate datasets. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2011, 79A, 167-174.	1.5	799
74	Plasma Levels of Soluble CD14 Independently Predict Mortality in HIV Infection. <i>Journal of Infectious Diseases</i> , 2011, 203, 780-790.	4.0	957
75	Design and Analysis of Crossover Trials for Absorbing Binary Endpoints. <i>Biometrics</i> , 2010, 66, 958-965.	1.4	33
76	Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses. <i>PLoS ONE</i> , 2010, 5, e9015.	2.5	125
77	Comparative Efficacy of Hemagglutinin, Nucleoprotein, and Matrix 2 Protein Gene-Based Vaccination against H5N1 Influenza in Mouse and Ferret. <i>PLoS ONE</i> , 2010, 5, e9812.	2.5	72
78	Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables. <i>Journal of Virology</i> , 2010, 84, 1631-1636.	3.4	304
79	Differential Specificity and Immunogenicity of Adenovirus Type 5 Neutralizing Antibodies Elicited by Natural Infection or Immunization. <i>Journal of Virology</i> , 2010, 84, 630-638.	3.4	57
80	Neutralizing Antibody Titers Conferring Protection to Macaques from a Simian/Human Immunodeficiency Virus Challenge Using the TZM-bl Assay. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 89-98.	1.1	40
81	Perforin Expression Directly Ex Vivo by HIV-Specific CD8+ T-Cells Is a Correlate of HIV Elite Control. <i>PLoS Pathogens</i> , 2010, 6, e1000917.	4.7	284
82	Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1. <i>Science</i> , 2010, 329, 856-861.	12.6	1,600
83	Public clonotype usage identifies protective Gag-specific CD8+ T cell responses in SIV infection. <i>Journal of Experimental Medicine</i> , 2009, 206, 923-936.	8.5	140
84	Regulatory T Cells Promote Early Influx of CD8 ⁺ T Cells in the Lungs of Respiratory Syncytial Virus-Infected Mice and Diminish Immunodominance Disparities. <i>Journal of Virology</i> , 2009, 83, 3019-3028.	3.4	120
85	Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies. <i>Journal of Virology</i> , 2009, 83, 188-199.	3.4	297
86	Conditioning in 2 ² Tables. <i>Biometrics</i> , 2009, 65, 316-322.	1.4	13
87	Biodistribution and Toxicological Safety of Adenovirus Type 5 and Type 35 Vected Vaccines Against Human Immunodeficiency Virus-1 (HIV-1), Ebola, or Marburg Are Similar Despite Differing Adenovirus Serotype Vector, Manufacturer's Construct, or Gene Inserts. <i>Journal of Immunotoxicology</i> , 2008, 5, 315-335.	1.7	49
88	Multivalent HA DNA Vaccination Protects against Highly Pathogenic H5N1 Avian Influenza Infection in Chickens and Mice. <i>PLoS ONE</i> , 2008, 3, e2432.	2.5	46
89	A High Viral Burden Predicts the Loss of CD8 T-Cell Responses Specific for Subdominant Gag Epitopes during Chronic Human Immunodeficiency Virus Infection. <i>Journal of Virology</i> , 2007, 81, 13809-13815.	3.4	13
90	A West Nile Virus DNA Vaccine Induces Neutralizing Antibody in Healthy Adults during a Phase 1 Clinical Trial. <i>Journal of Infectious Diseases</i> , 2007, 196, 1732-1740.	4.0	175

#	ARTICLE	IF	CITATIONS
91	Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. <i>Vaccine</i> , 2007, 25, 4085-4092.	3.8	134
92	HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. <i>Blood</i> , 2006, 107, 4781-4789.	1.4	1,681
93	Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts. <i>Toxicological Sciences</i> , 2006, 91, 610-619.	3.1	94
94	Effects of Lymphocyte Isolation and Timing of Processing on Detection of CD127 Expression on T Cells in Human Immunodeficiency Virus-Infected Patients. <i>Vaccine Journal</i> , 2005, 12, 228-230.	3.1	10
95	CARTscans: A Tool for Visualizing Complex Models. <i>Journal of Computational and Graphical Statistics</i> , 2004, 13, 807-825.	1.7	8
96	Likelihood-Based Data Squashing: A Modeling Approach to Instance Construction. <i>Data Mining and Knowledge Discovery</i> , 2002, 6, 173-190.	3.7	39